Clinical trials: Systemic Treatment
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer
Metastatic Melanoma, Metastatic Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response…
- Conditions
- Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- SERPENTINE (NCT04941365)
- Testing
- single arm
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Scleroderma, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
- Trial name
- NCT05085444
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University
COVID-19, Cytokine Storm
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. COVID-19 causes life threatening complications known as Cytokine Release Syndrome or Cytokine Storm and Acute Respiratory Distress…
- Conditions
- COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
- Trial name
- CORONA (NCT04378244)
- Testing
- DeltaRex-G
- Sponsor
- Aveni Foundation
Liver Insufficiency, Kidney Failure, Chronic
Quantification of Drugs and Their Degradation Products
The study includes two study parts in which blood is collected from the patients. Study part A (observational study, already received positive ethics committee vote; Our sign: 12-330): Use of blood samples gathered during routine…
- Conditions
- Liver Insufficiency, Kidney Failure, Chronic, Obesity, Pregnancy
- Trial name
- NCT01828372
- Testing
- additional blood withdrawals
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Cologne
Preeclampsia
A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia
The purpose of this study is a systematical registration of hemodynamic measurements (cardiac output, blood pressure and systemic vascular resistance) in women with serious preeclampsia.
- Trial name
- NCT00403572
- Volunteers
- 8 people
- Sponsor
- Oslo University Hospital
Mycoses
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
Invasive fungal infections are often life-threatening in persons with immunocompromise. Persons with prolonged neutropenia secondary to cytotoxic chemotherapies are at high risk for these infections.
- Trial name
- NCT00001757
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Disease, Chronic Obstructive
Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow…
- Trial name
- NCT02579772
- Testing
- N-acetylcysteine
- Volunteers
- 13 people
- Sponsor
- Queen's University
Acute Disease, Sepsis
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Research in acute care faces many challenges, including enrollment challenges, legal limitations in data sharing, limited funding, and lack of singular ownership of the domain of acute care.
- Conditions
- Acute Disease, Sepsis, Pneumonia, Frailty
- Trial name
- Acutelines (NCT04615065)
- Where
- Netherlands
- Volunteers
- 35,000 people
- Sponsor
- University Medical Center Groningen
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with…
- Trial name
- SOPHIA (NCT02492711)
- Testing
- Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
- Where
- 167 sites in United States, Austria and 16 more
- Volunteers
- 624 people
- Sponsor
- MacroGenics
Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an…
- Trial name
- NCT06871644
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Wound
Cleanser for Acute Wounds
The proposed study will be a prospective trial of management of acute traumatic wounds (less than 24 hours from injury and without previous intervention aside from a dressing for coverage).
- Trial name
- NCT05422144
- Testing
- Antimicrobial Skin & Wound Cleanser (AWC), Antimicrobial Wound Gel (AWG)
- Where
- United States
- Sponsor
- Rochal Industries LLC
Sepsis, Septic Shock
OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study
This study examines how well the Oxiris® hemofilter works over time in adults with septic shock who require continuous kidney support in the intensive care unit (ICU).
- Conditions
- Sepsis, Septic Shock, Blood Purification, Hemoadsorption
- Trial name
- OxiCLEAR (NCT07419802)
- Testing
- AN69-polyethylenimine hemofilter (Oxiris®) used for continuous veno-venous hemofiltration (CVVH)
- Where
- Latvia
- Volunteers
- 29 people
- Sponsor
- Pauls Stradins Clinical University Hospital
Psoriasis
Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features.
- Trial name
- NCT02162472
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Systemic Sclerosis, Scleroderma
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
- Trial name
- NCT06328777
- Testing
- CABA-201
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cabaletta Bio
ANCA-associated Vasculitis, Granulomatosis With Polyangiitis
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
The goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis…
- Conditions
- ANCA-associated Vasculitis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis
- Trial name
- BRAVO (NCT05716334)
- Where
- 9 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Serious Adverse Events, Patient Safety
Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events
Chemokeyp is a feasibility study testing a secure ED-Oncology interface for patients receiving chemotherapy who may present to unscheduled care with possible treatment-related complications.
- Conditions
- Serious Adverse Events, Patient Safety, Pharmacovigilance, Oncology
- Trial name
- NCT07592234
- Where
- Ireland
- Volunteers
- 100 people
- Sponsor
- St Vincent's University Hospital, Ireland
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Study of M5049 in CLE and SLE Participants
This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- Trial name
- NCT04647708
- Testing
- M5049
- Where
- 12 sites in Bulgaria, Germany and 4 more
- Volunteers
- 25 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Mesenchymal Stromal Cell, Systemic Sclerosis
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
Mesenchymal stromal cells (MSC) are multipotent cells which carry immunomodulatory, pro-angiogenic and anti-fibrotic properties, that can target Systemic Sclerosis (SSc) pathogenesis and its clinical manifestations.
- Trial name
- Pre_MSC-AT-SSc (NCT05947682)
- Testing
- Adipose tissue harvesting
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris